Who Decides What Counts as a Research Chemical?

Several bodies do, and none of them uses the phrase. Medicines regulators, chemicals regulators and customs authorities all have something to say about a given substance, but each is answering a different question, and "research chemical" is not a term any of them has defined. Search the statute books of any major jurisdiction and it will not be there as a category with a legal test attached.

That is genuinely the answer rather than an evasion of one. The question assumes a single classifier — one desk where somebody stamps substances as research chemicals — and no such desk exists. What exists is a set of separate regimes, drafted at different times for different purposes, whose boundaries a given substance may cross, sit between, or fall outside altogether.

Understanding the shape of that is more useful than a definition would be, because it explains a puzzling everyday observation: why two confident sources can describe the same compound in completely incompatible terms without either of them being wrong. They are usually answering different questions from different regimes.

Why is research chemical not a legal category?

Because it describes an intention, and legal classification works from properties, presentation and lists instead. That mismatch is the root of nearly every confusion in this area.

Regimes classify by things that can be established externally: the molecular identity of a substance, its hazard profile, what claims are made about it, what it does in a body, whether it appears on a schedule, and how much of it is moving where. What a buyer privately means to do with a substance is not, on its own, one of those things. Building a legal category around a stated intention would produce a rule that changed depending on what someone said, which is precisely the property a workable classification cannot have.

The medicines side illustrates it neatly. The European definition of a medicinal product runs on two limbs — presentation and function — so a product is caught either because it is put forward as having properties for treating or preventing disease, or because it acts pharmacologically, immunologically or metabolically to restore, correct or modify physiological functions 1. Neither limb asks what the purchaser had in mind. The Court of Justice sharpened the second limb further, holding that a product does not become a medicine by function merely because it contains an active substance: the capacity has to be scientifically established, not merely possible, and the assessment is made case by case on the product's own characteristics 2.

So the phrase survives in trade because it is useful shorthand for a supply channel — material sold without a therapeutic claim, into a market that is not the pharmacy — and it is exactly that usefulness which prevents it becoming a legal term. It names a way of selling, not a property of a molecule.

What does each regulator actually control?

Different stages of a substance's life, which is why their answers rarely collide head-on. A medicines regulator is interested in claims and effects; a chemicals regulator in manufacture, hazard and supply; a customs authority in movement across a border. One substance can be simultaneously in scope for all three and out of scope for each of the others' concerns.

Chemicals regulation is the least discussed of the three and the most misunderstood. In the European system, registration and hazard duties attach to substances manufactured or placed on the market above threshold quantities, with scientific research and development handled differently: material used in research below a defined tonnage, supplied to a limited number of known recipients and not placed on the market to an undefined public, sits under a distinct set of obligations from ordinary commercial goods 3. That is a real distinction in law, and it is the closest thing in the chemicals regime to what the trade phrase gestures at — although it governs registration duties rather than deciding whether anything may be sold to anyone.

Border authorities form the third layer, and they are procedural rather than definitional. Customs legislation gives them powers over goods entering and leaving a territory — supervision, examination, temporary storage, and the various ways consignments can be released or disposed of 5. Customs does not decide what a substance is. It applies whatever classification the medicines and chemicals regimes have already produced, at the moment goods cross a line on a map.

How can lists of controlled substances keep up with new compounds?

By supplementing named lists with provisions written to catch substances nobody has listed yet. This is one of the clearest illustrations that classification is an administrative process rather than a fixed fact about a molecule.

A schedule is a list of named substances, and lists are inherently retrospective — something has to exist and be noticed before it can be added. Legislators recognised early that a system built only on names would always be a step behind chemistry, so several jurisdictions layered other mechanisms on top of the lists.

The United States approach is the most cited example. Its analogue provision states that a controlled substance analogue, to the extent it is intended for human consumption, is treated for the purposes of federal law as a substance in the most restrictive schedule 4. Note what that does: it makes the legal status of an unlisted compound turn on its relationship to a listed one and on an element of intent, rather than on whether a committee has yet written the name down. Other countries use generic definitions instead, describing a chemical family by its structural skeleton and permitted substitutions so that every member is covered at once.

The relevant point for classification is structural, and it is worth stating plainly rather than tactically. These provisions were drafted precisely because the space between named substances is not a permanent gap in the law but a temporary one that legislatures actively work to close, by scheduling decisions, by generic definitions and by analogue clauses. A compound's absence from a list is therefore a fact about the list on a given date, and lists are revised.

Why does the same substance land in different categories in different countries?

Because every one of these authorities is national, and their founding definitions were drafted separately. There is no world body that classifies substances and no register that all countries share.

Divergence enters at several points. The starting definition of a medicinal product is not written identically everywhere, so the boundary between medicine, food supplement, cosmetic ingredient and laboratory reagent sits in a slightly different place in each system. Control schedules are compiled by national committees on national timetables, so the same compound may be listed in one country, under review in a second and unlisted in a third simultaneously. Chemicals duties are triggered by thresholds and definitions that differ between regimes.

Even identical wording does not guarantee identical outcomes. The Court of Justice was addressing this directly when it insisted that classification by function is a case-by-case assessment taking account of a product's composition, its pharmacological properties as currently established, the way it is used, how widely it is distributed and what consumers know of it 2. That is a judgement made on particular facts by a particular authority — and different authorities, looking at different evidence at different times, can reasonably reach different conclusions from the same text.

Add the border layer and the picture completes itself. Whether goods may enter a territory is decided by that territory's rules, applied by its own officials, regardless of how the goods were classified where they were dispatched 5. Two countries can hold opposite views of a substance, and both views are operative — each within its own territory, each administered by its own authority.

So who decides?

In practice, whichever authority is looking at the substance, in whichever country, under whichever regime applies to the situation in front of it. That is an uncomfortable answer, and it is also the accurate one.

The sequence is worth holding in mind. A medicines regulator can determine that something is a medicinal product by presentation or function and act on that. A drug control authority can determine that a substance is scheduled, or caught by a generic or analogue provision. A chemicals regulator can determine that registration or restriction duties apply. A customs authority can act at a border on whatever those determinations produce. Each decision is made under a different power, on a different test, and none of them consults the trade term.

What follows from that is a habit of mind rather than a rule. Any statement of the form "this compound is a research chemical" is an unfinished sentence: it names a supply channel while leaving the classification questions untouched. The versions that carry information are longer and more specific — is there an authorised product containing this substance in this market, is the substance scheduled in this country, what duties attach to supplying it here.

Those questions are answerable, but only jurisdiction by jurisdiction and only from primary sources — the relevant national authority's own register and control lists — with a qualified professional in that jurisdiction to interpret them. A phrase in a catalogue cannot substitute for any of it, and it was never designed to.